HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Henlius Biotech Co. Ltd.

https://www.henlius.com/en/index.html

Latest From Shanghai Henlius Biotech Co. Ltd.

Henlius Seeks To Add RA Indication To Chinese Rituximab

Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.

Biosimilars China

Oncology, Rare Disease Drugs Dominate New China Approvals

Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.

China Approvals

Henlius Kicks Off Denosumab Trial

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

Biosimilars Clinical Trials

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Biosimilars Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Fosun Pharma
    • Henlius Biopharmaceuticals
    • Shanghai Henlius Biotech, Inc.
    • Taiwan Henlix Biotech Co., Ltd.
    • Hengenix Biotech
UsernamePublicRestriction

Register